Viatris registers Phase 4 abuse-potential trial of gabapentin plus oxycodone
A single new trial listing covers the company's week, testing gabapentin's abuse potential when combined with oxycodone in recreational opioid users.
Viatris Inc.'s only registry update for the week is a newly listed Phase 4 study on gabapentin and oxycodone.
- Trial NCT07813026, sponsored by Viatris Inc. with Dr. Vince Clinical Research as collaborator, is recruiting for a Phase 4 crossover study that enrolls an estimated 60 participants classified as healthy, non-drug-dependent recreational opioid users1. The study is designed to compare gabapentin doses of 600 mg and 1200 mg, given alone or combined with oxycodone 20 mg, against oxycodone alone and placebo1. Participants must qualify by drug history, as the protocol requires that they have used opioids for non-therapeutic purposes on at least 10 occasions within the last year and at least once in the 12 weeks before screening1. The trial's primary measure is the maximum effect on a bipolar Visual Analog Scale for "Drug Liking," which assesses how much a participant likes or dislikes a drug effect, scored from 0 mm for strong disliking to 100 mm for strong liking1. The record lists primary completion as 2027-01-31 (estimated).
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.